Original Article

Could methylene blue be used to manage burning mouth syndrome? A pilot case series

Papa Abdou Lecor¹, Babacar Touré¹, Nathan Moreau²,³, Adeline Braud³,⁴, Wisam Dieb³,⁵, Yves Boucher³,⁵,∗

¹ Service de Physiologie, Département d’Odontologie, Université Cheikh Anta Diop, Dakar, Senegal
² Service de Médecine Bucco-Dentaire, Hôpital Bretonneau Paris, AP-HP, France
³ Université de Paris, LaBNOF (EA 7543), 75006 Paris, France
⁴ Service d’Odontologie, Hôpital Rothschild, AP-HP, Paris, France
⁵ Service d’Odontologie, Groupe hospitalier Pitié-Salpêtrière, AP-HP, Paris, France

(Received: 26 September 2019, accepted: 12 January 2020)

Keywords:
Trigeminal pain / orofacial nociception / neuropathy / glossodynia / stomatodynia / methylthioninium chloride

Abstract – Objective: Burning mouth syndrome is a disabling condition of complex pathophysiology characterized by spontaneous pain felt in the oral mucosa in the absence of evident mucosal lesions which lacks efficient treatments to this day. The purpose of this study was to demonstrate the efficacy of methylene blue in the management of burning mouth syndrome. Methods: The study was conducted at the dental clinic of the Anta Diop University and Newtown dental clinic of Dakar, Senegal. A solution of methylene blue as a mouth-rinse (0.5%) was applied for 5 minutes in five patients satisfying the ICHD-3 diagnostic criteria for burning mouth syndrome. This procedure was repeated every 6 hours 3 times per 24h, during 7 days. Using numeric rating scale, pain severity was assessed as the mean pain felt during the last day of application. Results: After 7 days, the pain was significantly reduced by two-thirds and almost absent at 3 and 6 months follow-up. No secondary effects of the use of methylene blue were observed. Putative mechanisms of action and potential implications for treatment are discussed. Conclusion: Methylene blue is an old compound but a novel topical therapy that could prove beneficial in the management of burning mouth syndrome.

Introduction

Burning mouth syndrome (BMS) is a disabling condition characterized by spontaneous pain felt in the oral mucosa, defined by the International Headache Society (IHS) [1] as “intraoral burning or dysesthetic sensation, which occurs daily for more than 2 hours and persists for more than 3 months, without clinically obvious causal lesions” (ICHD-3) [1]. As opposed to secondary BMS which has a causal factor [2], primary or idiopathic BMS is of unknown etiology. The prevalence of BMS affects between 0.01% and 3.7% in the adult population but can be much higher in specific patient groups such as menopausal women (12–40%); the average sex-ratio is approximately 1 man for 7 women, depending on the studies [3,4].

The characteristics of BMS have been comprehensively reviewed with focus on its historical [5,6], clinical [2,7], and pathophysiologic [8–12] characteristics. Accumulating evidence suggest that BMS is a neuropathic condition experienced by patients presenting morphological and functional alterations in both the peripheral and central nervous system, detectable at the subclinical level. Although often described as a clinically homogenous entity, BMS might refer to different conditions [9,13–15].

Regarding BMS therapy, several comprehensive reviews and meta-analysis [2,16–23] overall indicate both a lack of satisfactory treatments and a poor level of evidence of the existing studies with few randomized controlled trials (RCTs). Considering the disabling nature of BMS, including alterations of quality of life and social integration [13,24,25], high levels of somatic and psychiatric/psychological comorbidities [26–31], the need for efficient treatment is crucial for patients and a public health issue. To address such an issue, the 2016 Cochrane review [20] suggests designing well controlled RCTs and identifying new therapeutic approaches.

Methylene Blue (MB)

In Senegal, some patients spontaneously use Methylene Blue (MB) to alleviate oral pain, although no recommendation for this indication can be found in the literature. MB is a
cationic heterocyclic aromatic chemical compound (Methylthioninium Chloride) that has been used for more than 130 years in Medicine as a vital dye with very low tissue toxicity [32]. Among its many medical effects such as detoxification, disinfection and positive psychotropic effects [33], it has shown analgesics effects in rheumatology, orthopedics [34,35] and dermatology [35–45] and in experimental pain [46]. Interestingly MB has even shown analgesic effects in both orofacial pain conditions [47,48] and neuropathic pain [40,49] which prompted us to consider it as a possibly viable treatment option for BMS.

The aim of this study was therefore to test the putative analgesic effect of MB mouth-rinses in Burning Mouth Syndrome in an open case study.

Patients and methods

This pilot study was conducted between May 2019, and December 2019 at the dental clinic of the Anta Diop University and Newtown dental clinic of Dakar, Senegal. A prospective report of 5 consecutive cases of MB treatment for idiopathic BMS was conducted. The study protocol was approved by the Institutional Review Board of the Dental School. Inclusion criteria were age >18 years old, orofacial pain satisfying the ICHD-3 diagnostic criteria for BMS [1] (Tab. I), no impairment in communication. All patients gave oral and written consent to be treated with MB in the absence of other effective treatment options. Each patient also gave his/her informed written consent to participate in the study. Every patient underwent a thorough medical history, extra and intraoral clinical examination. Known contraindications for the use of MB were specifically searched (i.e. glucose-6-phosphate dehydrogenase deficiency, severe renal dysfunction, pregnancy, high risk for serotoninergic syndrome). The risk for bronchial aspiration was assessed and considered minimal/inexistent for patients with normal cognitive status and the ability to perform gargling. paraclinical tests were performed including oral candida search, ferritin, vitamin B6, B9 and B12 and thyroid hormones levels.

All patients satisfying the inclusion criteria for BMS were proposed MB for the management of their BMS symptoms. A solution of MB diluted to 0.5% in normal saline (100 mL total) was prepared. Patients were instructed to take a mouthful of the solution, hold it in the mouth on the painful sites for 5 minutes, and then gargle and spit. These steps were to be repeated every 6 hours 3 times per 24h, during 7 days. Pain severity was assessed as the mean pain felt during the last day on a 11 point numeric rating scale [NRS] (0 was defined as the absence of pain and 10 the maximal pain imaginable). Pain score was assessed as baseline (D0) before MB application and at three time points (D3, D5 D7) after MB application, and after 3 and 6 months. Patients were also asked to report any unpleasant sensation or adverse effect relating to MB use. Self-evaluated general Quality of Life and Stress/anxiety was noted as Good or Bad and Yes or No. Statistical analyses were performed using GraphPad software. Pain intensity ratings before (D0) and after MB mouthrinse at D7, 3M and 6M use were compared using ANOVA followed by Dunns post-tests. The level of significance was fixed at 0.05.

Results

The sample comprised 5 patients, all women, with a mean age of 58.8 years old (from 53 to 65 years), the characteristics of which are described in Table II. Five patients were diagnosed

<table>
<thead>
<tr>
<th>Table I. Diagnostic criteria of the ICHD-3 (2018) for BMS.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Oral pain fulfilling criteria B and C</td>
</tr>
<tr>
<td>B. Recurring daily for &gt;2 hours/day for &gt;3 months</td>
</tr>
<tr>
<td>C. Pain has both of the following characteristics:</td>
</tr>
<tr>
<td>1. burning quality</td>
</tr>
<tr>
<td>2. felt superficially in the oral mucosa</td>
</tr>
<tr>
<td>D. Oral mucosa is of normal appearance and clinical examination including sensory testing is normal</td>
</tr>
<tr>
<td>E. Not better accounted for by another ICHD-3 diagnosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table II. Characteristics of the BMS patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
</tr>
<tr>
<td>Age (y.o.)</td>
</tr>
<tr>
<td>Quality of pain</td>
</tr>
<tr>
<td>Location</td>
</tr>
<tr>
<td>Duration of the symptoms</td>
</tr>
<tr>
<td>Pain pattern</td>
</tr>
<tr>
<td>Alleviated by eating</td>
</tr>
<tr>
<td>Dysgeusia</td>
</tr>
<tr>
<td>Xerostomia</td>
</tr>
<tr>
<td>Stress/Anxiety</td>
</tr>
</tbody>
</table>
as primary BMS; Patient 5 had vitamin B9 and B12 deficiency which were corrected by supplementation, with no alleviation of the symptoms, before administration of MB. Two patients also reported dysgeusia. Evolution of the pain score from baseline to Day 7 showed a significant decrease (M = 7.0 ± 0.79 at D0 vs M = 2.0 ± 0.35 at D7; p < 0.05, Wilcoxon) (Fig. 1). No side effect or discomfort was reported. The relief of the pain in patient 5 was accompanied by a slight self-reported amelioration of the dysgeusia. At 3 and 6 months, mean scores of pain were significantly decreased compared to baseline. Means scores ± SEM were respectively 0.2 ± 0.22 and 0.4 ± 0.27; p < 0.05, with no adverse effect (Tabs. III and IV). No staining of the teeth was observed during the course of the study.

Discussion

The main result of this study is a significant long term decrease in the pain score for the 5 BMS patients tested for MB. Pain was completely relieved in 4 patients. These results are encouraging considering the lack of efficacy and side effects of available treatments and the low cost and safety of MB. Nevertheless, in the absence of a placebo-controlled group comparison, the proportion of placebo-mediated therapeutic effect cannot be properly assessed. A randomized controlled trial is under preparation to address this critical issue.

Using MB for pain therapy

MB is approved by the US Food and Drug Administration (FDA) for methemoglobinemia, prevention of urinary tract infections in elderly patients, and intraoperative visualization of nerves, nerve tissues, and endocrine glands as well as of pathologic fistulae [32]. MB is used either as a topical or an injectable agent, intradermally or intravenously. Since the first reports of its positive effects in the treatment of neuritic and rheumatic diseases, it has been used in dermatology for the

---

**Table III.** Characteristics of the BMS patients 3 months after MB treatment. VAS = Visual Analogic Scale (VAS). USF/SSF = Unstimulated and Stimulated Salivary Flow.

<table>
<thead>
<tr>
<th>Quality of pain</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAS Pain Score</td>
<td>No pain</td>
<td>No pain</td>
<td>No pain</td>
<td>No pain</td>
<td>Slight burning, relieved during mealtimes</td>
</tr>
<tr>
<td>Teeth coloration</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>1</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Slight metallic taste</td>
</tr>
<tr>
<td>Xerostomia</td>
<td>No</td>
<td>No</td>
<td>Yes but salivary flow was normal: USF: 0.35ml/min SSF: 2ml/min</td>
<td>No</td>
<td>Yes, USF was slightly decreased: 0.2ml/min SSF normal: 2ml/min</td>
</tr>
<tr>
<td>Stress/Anxiety</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Moderate stress related to family problems</td>
<td>Stress related to a slight persisting burning sensation</td>
</tr>
<tr>
<td>Quality of life</td>
<td>Good</td>
<td>Good</td>
<td>Good</td>
<td>Good</td>
<td>Moderate but improved since MB treatment</td>
</tr>
</tbody>
</table>
treatment of itch [41–45] and especially for intractable itch which can be viewed as a neuropathic condition [50]; in anal surgery [37,52] a recent meta-analysis concluded to significant improvement of pain after anorectal surgery [36] or in orthopedics where injection of MB in the radicular disc was used for treating chronic low back pain [35] but with controversial effects [34].

Orofacial pain

To the best of our knowledge, only two studies have documented the analgesic effects of MB in specific orofacial pain conditions. Aghanohosseini et al. (2006) in an open study of 13 patients with Oral Lichen Planus (OLP) lesions found a significant reduction in VAS scores before and after MB [47]. However in this study MB was given in combination with laser irradiation which makes difficult to attribute solely the effects to MB. No attempt to characterize the mechanisms involved in the pain relief was done although it can be supposed that it involved an anti-inflammatory effect, as OLP is a chronic inflammatory mucos-cutaneous disease. These results were reinforced by those of Sadaksharam et al. 2012 who observed a reduction in the size of OLP lesions although no assessment of pain was reported [53]. In another inflammatory painful oral condition i.e. oral mucositis following irradiation, Roldan et al. [48] reported a series of 5 consecutive patients with intractable pain associated with oral mucositis. The use of 0.5% methylene blue as mouth rinse resulted in a sustained analgesia over 3 weeks i.e. reduction of pain VAS score from 7.2 to 0.8, with a concomitant significant decrease of opioid use. If inflammatory mechanisms are clearly involved in oral mucositis, neuropathic mechanisms can also participate in its pathophysiology [54].

Since BMS is now recognized as a complex condition with neuropathic alterations [9], the analgesics effects observed in our study echo the pain relief obtained in a small double-blind, prospective, randomized controlled study of intravenous MB in patients with different types of neuropathic pain [49]. The authors observed a significant decrease in pain scores compared with the control group, and 3 of the 6 patients with dynamic mechanical allodynia showed an improvement in tactile allodynia after MB treatment. More recently, Zhao et al. 2018 investigated the effect of MB injection for post-herpetic neuralgia (PHN) and evidenced a significant reduction in VAS score associated with a reduction of plasmatic levels of IL-6, TNF-α and cortisol [40].

As this study did not seek to elucidate the underlying mechanisms of the observed analgesic effects, we can only speculate as to the mechanisms involved. Many of the several biological properties of MB rely on its ability to form a redox couple with leucomethylene blue functioning as a reversible oxidation reduction system or electron donor-acceptor couple in presence of NADPH, O₂ and iron containing compounds [49,55–57]. Animal studies as well as human studies have evidenced several relevant mechanisms [32,56,58], among them: the inhibition of both constitutive and inducible NOS (Nitric Oxide Synthase) resulting in decreased production of the proinflammatory NO and concomitant inhibition of guanylate cyclase; inhibition of arachidonic acid metabolism; deactivation of xanthine oxidase; MB is also a powerful antioxidant preventing cellular oxygen consumption and reduces mitochondrial superoxide and reactive free radical production, thereby providing neuronal protection [37,51]. MB might reduce peripheral nociceptive nerve fiber density in painful areas [37,41,43], inactivate microglia which is a well-known player in neuropathic pain, antagonize N-methyl-D-aspartate receptor. MB has a broad range of targets encompassing multiple neurotransmitter systems, ion channels, and enzymes involved in various neurophysiological functions. In addition MB inhibits monoamine oxidase (MAO) which breaks down catecholamines, resulting in positive anxiolytic and antidepressant effects [59,60]. This effect led to the development of the phenothiazine neuroleptic family.

Table IV. Characteristics of the BMS patients 6 months after MB treatment. VAS = Visual Analogic Scale (VAS). USF/SSF = Unstimulated and Stimulated Salivary Flow.

<table>
<thead>
<tr>
<th>Quality of life</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAS Pain score</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Teeth coloration</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Dysguesia</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Xérostomia</td>
<td>No</td>
<td>No</td>
<td>Yes, at waking time, SF normal</td>
<td>No</td>
<td>Slight metallic taste</td>
</tr>
<tr>
<td>Stress/Anxiety</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Moderate stress related to family problems and the burning pain</td>
<td>Stress related to the persistent burning pain</td>
</tr>
<tr>
<td>Quality of life</td>
<td>Good</td>
<td>Good</td>
<td>Good</td>
<td>Moderate but clearly improved since MB treatment</td>
<td>Moderate but clearly improved since MB treatment</td>
</tr>
</tbody>
</table>
Toxicity/adverse effects of MB

Toxicity is low and adverse reactions of MB injections (epidural, intravenous or intradermal) are rare [37,38,61–63] and mainly consist of a green or blue urine discoloration [64] although more severe incidents have been reported [65]. However intrathecal injection of MB can cause severe neurotoxic effects [55,66]. MB i.v. must also be given with caution to patients with a history of glucose-6-phosphate dehydrogenase deficiency [67] and those with severe renal impairment since MB has a renal elimination. MB is teratogenic and should not be used in pregnant patients [68]. In addition, there is a risk of serotonin syndrome when MB is injected in patients treated with inhibitors of the reuptake of serotonin such as selective serotonin reuptake inhibitors, tricyclic antidepressants, other monoamine oxidase inhibitors (MAOIs), serotonin–norepinephrine reuptake inhibitors, triptans, and ergot alkaloids [69].

All these effects have been reported after injections. To the best of our knowledge, no adverse effect has been reported with topical use. It is also noteworthy that BM is used in taste disorders, 73 and should not be used in pregnant patients [68]. In addition, there is a risk of serotonin syndrome when MB is injected in patients treated with inhibitors of the reuptake of serotonin such as selective serotonin reuptake inhibitors, tricyclic antidepressants, other monoamine oxidase inhibitors (MAOIs), serotonin–norepinephrine reuptake inhibitors, triptans, and ergot alkaloids [69].

Limits of the study

The first limitations of the study are the low sample size and the design of the study which do not allow a high level of evidence (such as the evaluation of non-specific placebo effect). Second MB analgesic effects have only been tested on the short term. Placebo and Hawthorne effects might also affect the results, although a study showed no significant placebo effect of topically administrated medication in BMS patients [73].

Conclusion

Methylene blue is an old compound but a novel topical therapy that could prove beneficial in the management of BMS. Larger studies, with a prospective double-blind randomized placebo-controlled design, are warranted to assess the long-term efficacy, side effects, and complications of oral methylene blue rinse in patients with mucosal pain.

Conflicts of interests: The authors declare that they have no conflicts of interest in relation to the publication of this article.

References


